VA Primary Care and Mental Health Providers’ Comfort with Genetic Testing: Survey Results from the PRIME Care Study

  • Leland E. HullEmail author
  • Kevin G. Lynch
  • David W. Oslin
Concise Research Reports


Pharmacogenetic (PGx) tests could transform how we prescribe medications. PGx tests assess whether a patient has specific genetic variants that could affect their likelihood of treatment response or risk of an adverse drug reaction.1 Currently, providers may order a variety of genetic tests in their clinical practice, including tests for disease susceptibility and diagnosis. PGx tests likely represent the next wave of genetic testing offered in the clinic, especially given the development of PGx test panels. PGx test panels check for multiple gene-drug interactions to guide medication selection for common conditions, such as depression and chronic pain. Anticipating that adoption of these tests will continue to expand as part of routine clinical care, we felt it important to delineate provider’s current knowledge of and experience with PGx testing.

Few surveys have assessed physicians’ knowledge and attitudes towards PGx.2,3In this report, we present data from a baseline...



We are grateful to the PRIME Care site principal investigators and their teams who enrolled and administered the survey to study providers: Muhammad Aslam, MD; Steven L. Batki, MD; Frederic Blow, PhD; James M. Bjork, PhD; Lisa Brenner, PhD; Peijun Chen, MD, PhD; Shivan Desai, MD; Eric Dieperink, MD; Richard Douyon, MD, FAPA; Scott Fears MD, PhD; Joel Gelernter, MD; Gretchen Haas, PhD; Amy Helstrom, PhD; Robin Hurley, MD; George Jurjus, MD; Julie Kreyenbuhl, PhD, PharmD; Steven Lieske, MD, PhD; Stephen Marder, MD; Cristina Montalvo, MD; Michael Ostacher, MD; Gayla Paschall, PhD; Paul Pfeiffer, MD; Jeffrey Pyne, MD; Mohini Ranganathan, MD; Joseph Simonetti, MD; Courtney Slough-Goodman, PharmD; Stuart Steinhauer, PhD; Trisha Suppes, MD, PhD; George Uhl, MD, PhD; Jason Vassy, MD; Gerardo Villarreal, MD; Amanda Wood, PhD.

Funding Information

Dr. Hull is supported by the Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Health Services Research, the Center for Healthcare Organization and Implementation Research (CHOIR), VA Boston Healthcare System. This research was funded by a VA Office of Research and Development awarded to Dr. David Oslin (SDR 16-348; ID: NCT03170362).

Compliance with Ethical Standards

This study was approved by the Department of Veterans Affairs Central Institutional Review Board.

Conflict of Interest

The authors declare that they do not have a conflict of interest.


  1. 1.
    Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature 2015;526:343–50.CrossRefGoogle Scholar
  2. 2.
    Stanek EJ, Sanders CL, Taber KA, et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther. 2012;91:450–8.CrossRefGoogle Scholar
  3. 3.
    Haga SB, Burke W, Ginsburg GS, Mills R, Agans R. Primary care physicians’ knowledge of and experience with pharmacogenetic testing. Clinical genetics 2012; 82:388–94.CrossRefGoogle Scholar
  4. 4.
    PRIME Care (PRecision Medicine In MEntal Health Care). Available at: Accessed 10/31/18.
  5. 5.
    Haga SB, Moaddeb J. Comparison of delivery strategies for pharmacogenetic testing services. Pharmacogenet Genomics 2014;24:139–45.CrossRefGoogle Scholar

Copyright information

© Society of General Internal Medicine (This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply)  2018

Authors and Affiliations

  • Leland E. Hull
    • 1
    Email author
  • Kevin G. Lynch
    • 2
    • 3
  • David W. Oslin
    • 2
    • 3
  1. 1.Center for Healthcare Organization and Implementation Research, VA Boston Healthcare SystemBostonUSA
  2. 2.Perelman School of MedicineUniversity of PennsylvaniaPhiladelphiaUSA
  3. 3.Corporal Michael J. Crescenz VA Medical CenterPhiladelphiaUSA

Personalised recommendations